The therapeutic effect of Ensifentrine on chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a disease with airflow limitation and chronic airway inflammation as its core pathological characteristics. It affects hundreds of millions of patients worldwide and seriously affects the quality of life and longevity of patients. In recent years, with the deepening understanding of the pathogenesis of COPD, treatment strategies have continued to evolve, and multi-target treatments targeting inflammation and airway spasm have become a research hotspot. Ohtuvayre (Ensifentrine)-Ensefentine Inhalation Suspension Solution As the first dual phosphodiesterase3 and 4 inhibitor, it has shown unique advantages in the treatment of COPD.

Exefentine exerts bronchial smooth muscle relaxation by inhibitingPDE3, effectively relieving airway spasm and rapidly improving lung function, especially FEV1 (forced expiratory volume in first second). At the same time, by inhibiting PDE4, exefentine can inhibit the release of inflammatory cells and mediators in the airways, reduce inflammatory responses, relieve airway inflammation, and fundamentally improve the pathological state of COPD. This dual mechanism enables exefantine to not only improve respiratory function, but also delay disease progression and reduce acute exacerbations.

Clinical studies have shown that ensefentin, as an inhaled therapeutic drug, can significantly improve patients' lung function indicators and exercise tolerance in a short period of time, reduce dyspnea, and improve patients' daily activities and quality of life. Its good safety and tolerance also provide guarantee for long-term maintenance treatment. Especially in patient groups where traditional bronchodilators and hormone treatments are ineffective, the application of exefantine brings new hope for treatment.

In addition, exefentine can be used in combination with other commonly used inhaled drugs to exert a synergistic effect and further optimize the COPD management plan. Its rapid onset of action also makes it have certain potential in adjuvant treatment of acute exacerbations, helping patients quickly relieve symptoms.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html